Ectodomain shedding of receptor activator of NF-κB ligand

Advances in Experimental Medicine and Biology

Volumn 602, Issue , 2007, Pages 15-21

  Hikita, Atsuhiko ^a   Tanaka, Sakae ^b  

^a National Hospital Organization   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE 14; OSTEOCLAST DIFFERENTIATION FACTOR; PERVANADATE; PROTEIN NOXA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; OSTEOPROTEGERIN;

CELL MATURATION; CELL MIGRATION; CONFERENCE PAPER; DOWN REGULATION; EXTRACELLULAR SPACE; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TUMOR CELL; ANIMAL; BONE DEVELOPMENT; CELL LINE; ENZYMOLOGY; METABOLISM; OSTEOBLAST; OSTEOSARCOMA; PHYSIOLOGY; REVIEW;

ANIMALS; CELL LINE; HUMANS; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; NF-KAPPA B; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; OSTEOSARCOMA; RANK LIGAND;

EID: 38449087683     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-72009-8_2     Document Type: Conference Paper

References (37)

1. Anderson, D.M., E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. Tometsko, E.R. Roux, M.C. Teepe, R.F. DuBose, D. Cosman, and L. Galibert. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179.
2. Black, R.A., C.T. Rauch, C.J. Kozlosky, J.J. Peschon, J.L. Slack, M.F. Wolfson, B.J. Castner, K.L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K.A. Schooley, M. Gerhart, R. Davis, J.N. Fitzner, R.S. Johnson, R.J. Paxton, C.J. March, and D.P. Cerretti. 1997. A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells. Nature 385: 729-733.
3. Buxbaum, J.D., K.N. Liu, Y. Luo, J.L. Slack, K.L. Stocking, J.J. Peschon, R.S. Johnson, B.J. Castner, D.P. Cerretti, and R.A. Black. 1998. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273: 27765-27767.
4. Chesneau, V., J.D. Becherer, Y. Zheng, H. Erdjument-Bromage, P. Tempst, and C.P. Blobel. 2003. Catalytic properties of ADAM19. J Biol Chem 278: 22331-22340.
5. Dougall, W.C., M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt,, E. Daro, J. Smith, M.E. Tometsko, C.R. Maliszewski, A. Armstrong, V. Shen, S. Bain, D. Cosman, D. Anderson, P.J. Morrissey, J.J. Peschon, and J. Schuh. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev 13: 2412-2424.
6. Fata, J.E., Y.Y. Kong, J. Li, T. Sasaki, J. Irie-Sasaki, R.A. Moorehead, R. Elliott, S. Scully, E.B. Voura, D.L. Lacey, W.J. Boyle, R. Khokha, and J.M. Penninger. 2000. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103: 41-50.
7. Guo, L.J., H. Xie, H.D. Zhou, X.H. Luo, Y.Q. Peng, and E.Y. Liao. 2004. Stimulation of RANKL and inhibition of membrane-type matrix metalloproteinase-1 expression by parathyroid hormone in normal human osteoblasts. Endocr Res 30: 369-377.
8. Hikita, A., Y. Kadono, H. Chikuda, A. Fukuda, H. Wakeyama, H. Yasuda, K. Nakamura, H. Oda, T. Miyazaki, and S. Tanaka. 2005. Identification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding. J Biol Chem 280: 41700-41706.
9. Hikita, A., Yana, I., Wakeyama, H., Nakamura, M., Kadono, Y., Oshima, Y., Nakamura, K., Seiki, M., and Tanaka, S. 2006. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-Kappa B ligand. J Biol Chem 281: 36846-36855
10. Holmbeck, K., P. Bianco, J. Caterina, S. Yamada, M. Kromer, S.A. Kuznetsov, M. Mankani, P.G. Robey, A.R. Poole, I. Pidoux, J.M. Ward, and H. Birkedal-Hansen. 1999. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99: 81-92.
11. Itoh, K., N. Udagawa, K. Matsuzaki, M. Takami, H. Amano, T. Shinki, Y. Ueno, N. Takahashi, and T. Suda. 2000. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J Bone Miner Res 15: 1766-1775.
12. Jones, D.H., T. Nakashima, O. Sanchez, I. Kozieradzki, S.V. Komarova, I. Sarosi, S. Morony, E. Rubin, R. Sarao, C.V. Hojilla, V. Komnenovic, Y.Y. Kong, M. Schreiber, S.J. Dixon, S.M. Sims, R. Khokha, T. Wada, and J.M. Penninger. 2006. Regulation of cancer cell migration and bone metastasis by RANKL. Nature Mar 30;440(7084): 692-696.
13. Koike, H., S. Tomioka, H. Sorimachi, T.C. Saido, K. Maruyama, A. Okuyama, A. Fujisawa-Sehara, S. Ohno, K. Suzuki, and S. Ishiura. 1999. Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem J 343(Pt 2): 371-375.
14. Kong, Y.Y., H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, S. Morony, A.J. Oliveira-dos-Santos, G. Van, A. Itie, W. Khoo, A. Wakeham, C.R. Dunstan, D.L. Lacey, T.W. Mak, W.J. Boyle, and J.M. Penninger. 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
15. Kotake, S., N. Udagawa, M. Hakoda, M. Mogi, K. Yano, E. Tsuda, K. Takahashi, T. Furuya, S. Ishiyama, K.J. Kim, S. Saito, T. Nishikawa, N. Takahashi, A. Togari, T. Tomatsu, T. Suda, and N. Kamatani. 2001. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44: 1003-1012.
16. Kriegler, M., C. Perez, K. DeFay, I. Albert, and S.D. Lu. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53: 45-53.
17. Lacey, D.L., E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y.X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney, and W.J. Boyle. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
18. Lam, J., S. Takeshita, J.E. Barker, O. Kanagawa, F.P. Ross, and S.L. Teitelbaum. 2000. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106: 1481-1488.
19. Lammich, S., E. Kojro, R. Postina, S. Gilbert, R. Pfeiffer, M. Jasionowski, C. Haass and F. Fahrenholz. 1999. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 96: 3922-3927.
20. Li, Y.M., M.T. Lai, M. Xu, Q. Huang, J. DiMuzio-Mower, M.K. Sardana, X.P. Shi, K.C. Yin, J.A. Shafer, and S.J. Gardell. 2000. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A 97: 6138-6143.
21. Liao, E.Y., X.H. Luo, X.G. Deng, and X.P. Wu. 2001. Effects of 17beta-estradiol on the expression of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-2 in human osteoblastic MG-63 cell cultures. J Endocrinol Invest 24: 876-881.
22. Lum, L., B.R. Wong, R. Josien, J.D. Becherer, H. Erdjument-Bromage, J. Schlondorff, P. Tempst, Y. Choi, and C.P. Blobel. 1999. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274: 13613-13618.
23. Luo, X.H., and E.Y. Liao. 2001. Progesterone differentially regulates the membrane-type matrix metalloproteinase-1 (MT1 -MMP) compartment of proMMP-2 activation in MG-63 cells. Horm Metab Res 33: 383-388.
24. Luo, X.H., E.Y. Liao, X. Su, and X.P. Wu. 2004. Parathyroid hormone inhibits the expression of membrane-type matrix metalloproteinase-1 (MT1-MMP) in osteoblast-like MG-63 cells. J Bone Miner Metab 22: 19-25.
25. Lynch, C.C., A. Hikosaka, H.B. Acuff, M.D. Martin, N. Kawai, R.K. Singh, T.C. Vargo-Gogola, J.L. Begtrup, T.E. Peterson, B. Fingleton, T. Shirai, L.M. Matrisian, and M. Futakuchi. 2005. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7: 485-496.
26. Mizuno, A., T. Kanno, M. Hoshi, O. Shibata, K. Yano, N. Fujise, M. Kinosaki, K. Yamaguchi, E. Tsuda, A. Murakami, H. Yasuda, and K. Higashio. 2002. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab 20: 337-344.
27. Nakamura, M., N. Udagawa, S. Matsuura, M. Mogi, H. Nakamura, H. Horiuchi, N. Saito, B.Y. Hiraoka, Y. Kobayashi, K. Takaoka, H. Ozawa, H. Miyazawa, and N. Takahashi. 2003. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144: 5441-5449.
28. Nakashima, T., Y. Kobayashi, S. Yamasaki, A. Kawakami, K. Eguchi, H. Sasaki, and H. Sakai. 2000. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275: 768-775.
29. Schlondorff, J., L. Lum, and C.P. Blobel. 2001. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem. 276: 14665-14674.
30. Schneider, P., N. Holler, J.L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187: 1205-1213.
31. Selkoe, D.J. 1991. The molecular pathology of Alzheimer's disease. Neuron 6: 487-498.
32. Takahashi, N., T. Akatsu, N. Udagawa, T. Sasaki, A. Yamaguchi, J.M. Moseley, T.J. Martin, and T. Suda. 1988. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123: 2600-2602.
33. Vassar, R., B.D. Bennett, S. Babu-Khan, S. Kahn, E.A. Mendiaz, P. Denis, D.B. Teplow, S. Ross, P. Amarante, R. Loeloff, Y. Luo, S. Fisher, J. Fuller, S. Edenson, J. Lile, M.A. Jarosinski, A.L. Biere, E. Curran, T. Burgess, J.C. Louis, F. Collins, J. Treanor, G. Rogers, and M. Citron. 1999. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741.
34. Wong, B.R., J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F.S. Bartlett, 3rd, W.N. Frankel, S.Y. Lee, and Y. Choi. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272: 25190-25194.
35. Yamanaka, H., K. Makino, M. Takizawa, H. Nakamura, N. Fujimoto, H. Moriya, R. Nemori, H. Sato, M. Seiki, and Y. Okada. 2000. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in rheumatoid synovium. Lab Invest 80: 677-687.
36. Yasuda, H., N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi, and T. Suda. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95: 3597-3602.
37. Ziolkowska, M., M. Kurowska, A. Radzikowska, G. Luszczykiewicz, P. Wiland, W. Dziewczopolski, A. Filipowicz-Sosnowska, J. Pazdur, J. Szechinski, J. Kowalczewski, M. Rell-Bakalarska, and W. Maslinski. 2002. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46: 1744-1753.